AIDS-related tumors: Integrating antiviral and anticancer therapy

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 3, 2002, Pages 299-315

  Tirelli, Umberto ^a   Bernardi, Daniele ^a   Spina, Michele ^a   Vaccher, Emanuela ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

AIDS; HAART; HIV infection; Malignancies; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 6; NAVELBINE; PACLITAXEL; PREDNISOLONE; PROTEINASE INHIBITOR; SAQUINAVIR; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; MORTALITY; NONHODGKIN LYMPHOMA; PATHOGENESIS; REVIEW; RISK FACTOR; SURVIVAL RATE; UTERINE CERVIX CANCER; ANUS TUMOR; B CELL LYMPHOMA; NEOPLASM; UROGENITAL TRACT TUMOR; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ANUS NEOPLASMS; HUMAN; LYMPHOMA, AIDS-RELATED; NEOPLASMS; SARCOMA, KAPOSI; SUPPORT, NON-U.S. GOV'T; UROGENITAL NEOPLASMS; HUMANS;

EID: 0036009003     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00165-2     Document Type: Review

References (145)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. AIDS-related malignancies
3. AIDS-related malignancies: The emerging epidemic
4. Malignant lymphomas in a population at risk for acquired immunodeficiency syndrome
5. Unusual malignant tumors in 49 patients with HIV infection
6. Neoplastic complications of HIV infection
7. Increased incidence of Hodgkin's disease in homosexual men with HIV infection
8. Malignancies in the multicenter AIDS cohort study (MACS) 1984-1994
9. Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors
10. Declining incidence of Kaposi's sarcoma in AIDS Clinical Trials Group (ACTG) trials
11. Highly active antiretroviral therapy and incidence of cancer in HIV-infected individuals
12. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies in an urban medical center
13. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS
14. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin Lymphoma in persons with AIDS in Italy
15. Risk of cancer in people with AIDS
16. Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection?
17. The epidemiology of AIDS and associated tumors in Europe
18. Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy
19. Effect of antiretroviral therapy on recent trends in cancers among HIV-infected persons
20. Identification of herpes-virus-like DNA sequences in AIDS-associated Kaposi's sarcoma
21. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma
22. The expression of endothelial cell surface antigens by AIDS-associated Kaposi's sarcoma: Evidence for a vascular endothelial cell origin
23. AIDS-associated Kaposi's sarcoma-derived cells origin in long-term culture express and synthetize smooth muscle alpha-actin
24. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: Implications for AIDS-Kaposi's sarcoma pathogenesis
25. Tat protein of HIV-1 stimulates growth of AIDS-Kaposi's sarcoma-derived cells
26. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: A missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma
27. Therapy of AIDS and AIDS-associated neoplasms
28. Clinical aspects of Kaposi's sarcoma
29. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma
30. Kaposi's sarcoma: Advances and perspectives
31. The effects of preparations of human chorionic gonadotropin of AIDS-related Kaposi's sarcoma
32. Treatment of AIDS related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic) gel
33. Topical alitretinoin gel as treatment for cutaneous lesions of patients with AIDS-related Kaposi's sarcoma: Results of two multi-center, double-blind, vehicle controlled trials
34. Interferon and other biologic agents for the treatment of Kaposi's sarcoma
35. Prospective randomized trial of two dose levels of Interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network Study
36. Multicenter, randomized, open label phase II trial of two doses of interferon (IFN)- alfa2b with didanosine (ddI) in HIV-related Kaposi's sarcoma: ACTG 206
37. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor
38. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir
39. Patients with advanced AIDS-related Kaposi's sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy
40. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome
41. Treatment of the acquired immunodeficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent
42. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy
43. A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS
44. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma
45. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen
46. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma
47. Pegylated-lyposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomised phase III clinical trial
48. A phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin (Daunoxome) in the treatment of advanced AIDS-related Kaposi's sarcoma
49. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma
50. Efficacy of pegylated-lyposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
51. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
52. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma
53. Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma
54. The epidemiology of acquired immunodeficiency syndrome-related lymphomas
55. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individuals
56. Highly active antiretroviral therapy and incidence of cancer in HIV-infected individuals
57. A clinicopathologic study of lymphoid neoplasias associated with human immunodeficiency virus infection in Italy
58. CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: The first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus-related systemic lymphomas
59. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature
60. HHV-8 positive body cavity-based lymphoma: A novel lymphoma entity
61. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas
62. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection
63. Pathogenesis of AIDS-related lymphomas: Molecular and histogenetic heterogeneity
64. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy
65. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National institute of allergy and infectious diseases AIDS clinical trials group
66. Spontaneous regressions of an AIDS-related high-grade non-Hodgkin's lymphoma with HAART
67. Acquired immune deficiency syndrome-related pulmonary non-Hodgkin's lymphoma regressing after zidovudine therapy
68. Azothymidine and interferon-alpha are active in AIDS associated small non-cleaved cell lymphoma but not large-cell lumphoma
69. Complete remission of a primary effusion lymphoma with antiretroviral therapy
70. AIDS-associated non-Hodgkin's lymphoma in San Francisco
71. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
72. Prognostic factors in the treatment of human immunodefieciency virus-associated non-hodgkin's lymphoma: Analysis of AIDS clinical trials group protocol 142 - Low-dose versus standard dose m-BACOD plus granulocyte-macrophage colony-stimulating factor
73. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans affairs cooperative study group on AIDS
74. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
75. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reaction
76. Ongoing HIV dissemination during HAART
77. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
78. When should we start? Use of Markov modeling and decision analysis to evaluate the long-term implications of antiretroviral therapy
79. AIDS-related malignancies: The emerging epidemic
80. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus
81. Chemotherapy for HIV-NHL in combination with HAART
82. Concomitant CHOP chemotherapy and highly active antiretroviral therapy (HAART) in patients with HIV-related non-Hodgkin's lymphoma
83. Pilot trial of saquinavir and nucleoside analogues plus infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma
84. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
85. Phase II trial of infusional cyclophosphamide, doxorubicin, & etoposide (CDE) in HIV-associated non-Hodgkin's lymphoma (NHL): An Eastern Cooperative Oncology Group (ECOG) Trial (E1494)
86. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors
87. Rituximab for the treatment of AIDS-associated non-hodgkin's lymphoma (AIDS-NHL)
88. The spectrum of acquired immunodeficiency syndrome (AIDS)-associated malignancies in San Francisco, -1987
89. Rates of non-AIDS defining cancers in people with AIDS
90. Increased incidence of cancer among homosexual men, New York City and San Francisco, -1990
91. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases
92. Hodgkin's disease during HIV-1 infection: The French registry experience
93. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression
94. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease
95. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells
96. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
97. Human immunodeficiency virus-associated Hodgkin's disease
98. Hodgkin's disease in 92 patients with HIV infection: The Italian experience
99. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients
100. Association d'epirubicine, bleomycine, vinblastine et prednisone (EBVP) avant radiotherapie dans le stades localisés de la maladie de Hodgkin
101. Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF
102. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced stage Hodgkin's disease: A preliminary report
103. Feasibility of the integration of Stanford V chemotherapy regimen with highly active antiretroviral therapy (HAART) and G-CSF in patients with Hodgkin's disease and HIV infection
104. Invasive and preinvasive cervical neoplasia in human immunodeficiency virus-infected women
105. Human immunodeficiency virus infection and cervical neoplasia
106. Risk of invasive cervical cancer among women with, or at risk for, HIV infection
107. Human Papillomavirus-associated anogenital cancers in patients with HIV infection and AIDS
108. Colposcopic evaluation of human immunodeficiency virus-positive women
109. Histology/cytology discrepancies in HIV-infected obstetric patients with normal Pap smears
110. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human imunodeficiency virus
111. Human papillomavirus and cervical intraepithelial neoplasia in women with renal allografts
112. Treatment of carcinoma in situ: Evaluation of 1609 cases
113. Results of conservative management of cervical intraepithelial neoplasia
114. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical normalities
115. Systemic alpha-interferon treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: Double-blind, placebo-controlled trial
116. Chemoprevention of cancer of the uterine cervix: A study on chemoprevention of retinamide II from cervical precancerous lesione
117. Vaginal 5-fluorouracil for high grade cervical dysplasia in HIV-infected women: A randomized trial
118. Immunological parameters and cervical intraepithelial neoplasia (CIN) in HIV1+ women
119. Incidence of squamous intraepithelial lesions (SIL) in HIV infected women
120. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy
121. Characteristics of women with AIDS and invasive cervical cancer
122. Cervical cancer as an AIDS defining illness
123. Human immunodeficiency virus infection and genital warts as risk factors for anal intraepithelial neoplasia in homosexual men
124. Association between anorectal dysplasia, human papillomavirus and human immunodeficiency virus infection in homosexual men
125. Sexual practices, sexually trasmitted diseases, and the incidence of anal cancer
126. The epidemiology of AIDS-related neoplasms
127. Spectum of AIDS-associated malignant disorders
128. Anal neoplasia: Pathogenesis, diagnosis and management
129. Molecular virology and epidemiology of human papillomavirus and cervical cancer
130. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer
131. Anal cytology as a screening tool for anal squamous intraepithelial lesions
132. Anal and cervical abnormality in women-prediction by human papillomavirus tests
133. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women
134. Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women
135. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men
136. Anal squamous intraepithelial lesions in HIV-negative homosexual and bisexual men: Prevalence and risk factors
137. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men
138. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal
139. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer
140. Nonmelanoma skin cancers and infection with the human immunodeficiency virus
141. Therapy of non-small lung cancers (NSCLC) in patients with HIV infection
142. Lung carcinoma in 36 patients with human immunodeficiency virus infection
143. Non-AIDS defining malignancies in the Multicenter AIDS Cohort Study (MACS), 1984-1996
144. Testicular germ cell tumors and human immunodeficiency virus infection: A report of 26 cases